Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

31.40 -0.10 (-0.32%)

Streaming Delayed Price Updated: 3:52 PM EDT, Mar 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? ↗

February 16, 2025

Via The Motley Fool

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity ↗

February 10, 2025

Via Benzinga

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗

February 10, 2025

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Via Benzinga

Topics Intellectual Property

MarketBeat Week in Review – 02/03 - 02/07

February 08, 2025

Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

Teva Pharmaceutical Indus Options Trading: A Deep Dive into Market Sentiment ↗

January 30, 2025

Via Benzinga

What Analysts Are Saying About Teva Pharmaceutical Indus Stock ↗

January 30, 2025

Via Benzinga

Neurocrine Biosciences Reports Mixed Q4 ↗

February 07, 2025

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Via The Motley Fool

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

February 03, 2025

Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?

Via MarketBeat

NVIDIA, Teva Pharmaceutical And UPS Are Among Top Large Cap Losers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? ↗

February 02, 2025

Discover the latest trends with last week's worst-performing large-cap stocks, including Manhattan Associates' steep decline following reduced financial guidance and the broader impact of China's...

Via Benzinga

Topics Artificial Intelligence

Why Teva Pharmaceutical Stock Is Sinking Today ↗

January 29, 2025

Via The Motley Fool

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today ↗

January 27, 2025

Via Benzinga

Peering Into Teva Pharmaceutical Indus's Recent Short Interest ↗

January 27, 2025

Via Benzinga

Teva Pharmaceutical Industries (TEVA) Q4 2024 Earnings Call Transcript ↗

January 29, 2025

TEVA earnings call for the period ending December 31, 2024.

Via The Motley Fool

Topics Earnings

Crude Oil Down 1.5%; Teva Pharmaceutical Shares Plummet ↗

January 29, 2025

Via Benzinga

Stocks Tick Down Ahead Of Fed Meeting, Nvidia Jitters Resume, Trump Media Rallies: What's Driving Markets Wednesday? ↗

January 29, 2025

Caution dominates Wednesday's midday trading session in New York as investors anxiously await the Federal Open Market Committee decision at 2 p.m. ET.

Via Benzinga

Topics Economy Government

Stocks Scatter As Investors Prepare For Fed Remarks ↗

January 29, 2025

Stocks are mixed this afternoon, as investors await an interest rate update from the Federal Reserve's first policy meeting of 2025.

Via Talk Markets

Topics Economy Stocks / Equities

Nasdaq Down Over 100 Points; Corning Posts Upbeat Earnings ↗

January 29, 2025

Via Benzinga

Teva Pharmaceutical Posts Lower Revenue. Stock Slips. ↗

January 29, 2025

Teva stock retreated Wednesday after the pharmaceutical company reported a drop in fourth-quarter revenue.

Via Investor's Business Daily

Teva Pharmaceutical Stock Falls On Q4 Earnings: What's Going On? ↗

January 29, 2025

Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share,...

Via Benzinga

Manhattan Associates, LendingClub And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 29, 2025

Via Benzinga

Teva Delivers Second Consecutive Year of Growth; Announces Strong Financial Results in Fourth Quarter and Full Year 2024, Led by Generics Performance and Innovative Portfolio Growth

January 29, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data ↗

January 28, 2025

Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating IBD.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 27, 2025

Via Benzinga

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Applications for AVT05, a Proposed Biosimilar to Simponi® and Simponi Aria® (golimumab)

January 27, 2025

From Alvotech

Via GlobeNewswire

Earnings Scheduled For January 29, 2025 ↗

January 29, 2025

Via Benzinga

FDA Warns Of Severe Allergic Reaction Risk With Teva's Multiple Sclerosis Drug ↗

January 23, 2025

FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.

Via Benzinga

Promising Signs: TEVA PHARMACEUTICAL-SP ADR Setting the Stage for a Breakout. ↗

January 23, 2025

TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) has a good technical rating of 10 out of 10 and could possibly break out.

Via Chartmill

Teva Challenges Drug Price Law's Impact On Innovation, Generics ↗

January 17, 2025

Teva Pharmaceuticals challenges the Inflation Reduction Act, arguing CMS's drug pricing policies harm generics, biosimilars, and innovation, disrupting healthcare balance.

Via Benzinga

Topics Economy

January 17, 2025

HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.

Via Benzinga

Topics Economy

< Previous 1 2 3 4 5 6 7 8 9

...

32 33 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.